Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 5OTHER 4OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1Sarcoma 1Osteosarcoma 1Gastrointestinal Stromal Tumors 1Desmoplastic Small Round Cell Tumor 1Chondrosarcoma 1Bone Neoplasms 1Advanced Solid Tumor 1Advanced Gastric Adenocarcinoma 1

Interventions

Cisplatin 6Radiotherapy 4Hydralazine 3Gemcitabine 3Valproic Acid 2Probiotics 2Paclitaxel 2Drug Therapy 2Brachytherapy 2spartalizumab 1nimotuzumab 1belotecan 1apatinib 1Therapeutics 1Surgical Procedures, Operative 1Standard of Care 1Radiotherapy, Intensity-Modulated 1Radiation Dose Hypofractionation 1Proto-Oncogene Proteins c-raf 1Neoadjuvant Therapy 1Nelfinavir 1Mobile Health Units 1Magnetic Resonance Spectroscopy 1Magnesium 1Injections 1Immune Checkpoint Inhibitors 1Hysteroscopy 1Heart Rate 1Fatty Acids, Omega-3 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Uterine Cervical Neoplasms × spartalizumab × Clear all
NCT07472153 2026-05-28

PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer

N.N. Alexandrov National Cancer Centre

Phase 2/3 Recruiting
120 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡